Premenstrual Syndrome Diagnosis: A Comparative Study between the Daily Record of Severity of Problems (DRSP) and the Premenstrual Symptoms Screening Tool (PSST)

Abstract

Objective To validate the premenstrual symptoms screening tool (PSST) in relation to the daily record of severity of problems (DRSP) for premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) diagnoses.

Methods A cross-sectional study with 127 women (20–45 years) with PMS complaints. The women were evaluated in terms of weight, height and body mass index (BMI). After using the primary care evaluation of mental disorders (PRIME-MD) questionnaire to exclude the diagnosis of depression, the PSST was completed and the women were instructed to fill out the DRSP for two consecutive menstrual cycles. The agreement between the two questionnaires was assessed by the Kappa (k) and the prevalence-adjusted, bias-adjusted kappa (PABAK) values.

Results Two-hundred and eighty-two women met the eligibility criteria and answered the PSST. The DRSP was completed for two cycles by 127 women. The percentages of women with PMS and PMDD diagnoses by the DRSP were 74.8% and 3.9% respectively; by PSST, the percentages were41.7% and 34.6% respectively. The number of patients considered “normal” (with symptoms below the threshold for the diagnosis of PMS) was similar in both questionnaires. There was no agreement (Kappa = 0.12) in the results of PMS/ PMDD diagnosis (the PABAK coefficient confirmed this result = 0.39). The PSST had a high sensitivity (79%) and a low specificity (33.3%) for PMS/PMDD diagnosis.

Conclusion The PSST should be considered a diagnostic screening tool. Positive PMS/PMDD cases by PSST should be further evaluated by DRSP to confirm the diagnosis.

Resumo

Objetivo Validar o instrumento de rastreamento de sintomas pré-menstruais (PSST) em relação ao relato diário da gravidade dos problemas (DRSP) para o diagnóstico de síndrome pré-menstrual (SPM) e de transtorno disfórico pré-menstrual (TDPM).

Métodos Um estudo transversal com 127 mulheres entre 20 e 45 anos com queixas de SPM. As mulheres foram avaliadas quanto ao peso, à altura e ao índice de massa corporal (IMC). Depois de excluir o diagnóstico de depressão pelo questionário de avaliação de distúrbios mentais para atenção primária (PRIME-MD), o PSST foi respondido e as mulheres receberam orientações sobre como preencher o DRSP por dois meses. A concordância entre os dois questionários foi conduzida através do índice de Kapa (k) e pelo PABAK.

Resultados Duzentos e oitenta e duas mulheres com critérios elegíveis responderam ao PSST. O DRSP foi preenchido por dois ciclos por 127 mulheres. As porcentagens de mulheres com diagnósticos de SPM e de TDPM pelo DRSP foram de 74,8% e 3,9%, respectivamente; pelo PSST, as porcentagens foram de 41,7% e 34,6%, respectivamente. O número de pacientes consideradas “normais” (com sintomas abaixo do necessário para o diagnóstico de SPM) foi similar nos dois questionários. Análises demonstraram não haver concordância entre ambos os instrumentos para os resultados diagnósticos de SPM e TDPM (Kappa = 0,12, coeficiente de PABAK = 0,39). Para o diagnóstico de SPM/TDPM, o PSST apresentou uma alta sensibilidade (79%) e baixa especificidade (33,3%).

Conclusão O PSST é considerado uma ferramenta de triagem. Conclui-se que casos positivos de SPM/TDPM pelo PSST devem ser melhor investigados pelo DRSP para confirmar o diagnóstico.

Keywords

diagnosis - questionnaire - signs and symptoms - premenstrual syndrome - premenstrual dysphoric disorder

Palavras-Chave

diagnóstico - questionário - sinais e sintomas - síndrome pré-menstrual - transtorno disfórico pré-menstrual

Contributions

All authors listed above participated in the study to a significant extent. Henz A., Ferreira C. F., Fleck M. P. A. and Wender M. C. O. worked on analysis and interpretation of data, critically reviewed and revised the manuscript. Henz A., Oderich C. L., Gallon C. W., Castro J. R. S., Conzatti M., Fleck M. P. A. and Wender M. C. O. worked on the conception, design and data collection. All authors read and approved the submitted manuscript.

• References

• 1 Nillni YI, Rohan KJ, Zvolensky MJ. The role of menstrual cycle phase and anxiety sensitivity in catastrophic misinterpretation of physical symptoms during a CO(2) challenge. Arch Women Ment Health 2012; 15 (06) 413-422
• 2 Ryu A, Kim TH. Premenstrual syndrome: A mini review. Maturitas 2015; 82 (04) 436-440
• 3 Kessel B. Premenstrual syndrome. Advances in diagnosis and treatment. Obstet Gynecol Clin North Am 2000; 27 (03) 625-639
• 4 Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003; 28 (Suppl. 03) 1-23
• 5 Rodrigues IC, Oliveira E. Prevalência e convivência de mulheres com síndrome pré-menstrual. Arq Ciênc Saúde. 2006; 13: 146-152
• 6 Petta CA, Osis MJ, de Pádua KS, Bahamondes L, Makuch MY. Premenstrual syndrome as reported by Brazilian women. Int J Gynaecol Obstet 2010; 108 (01) 40-43
• 7 Miller FC. Ten goals for the American College of Obstetricians and Gynecologists for the first decade of the next millennium. Obstet Gynecol 2000; 95 (01) 1-5
• 8 Wittchen HU, Becker E, Lieb R, Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002; 32 (01) 119-132
• 9 Heinemann LA, Minh TD, Filonenko A, Uhl-Hochgräber K. Explorative evaluation of the impact of severe premenstrual disorders on work absenteeism and productivity. Womens Health Issues 2010; 20 (01) 58-65
• 10 Nevatte T, O'Brien PM, Bäckström T. , et al; Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. Arch Women Ment Health 2013; 16 (04) 279-291
• 11 O'Brien PM, Bäckström T, Brown C. , et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Women Ment Health 2011; 14 (01) 13-21
• 12 Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Women Ment Health 2006; 9 (01) 41-49
• 13 Borenstein JE, Dean BB, Yonkers KA, Endicott J. Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. Obstet Gynecol 2007; 109 (05) 1068-1075
• 14 Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Women Ment Health 2003; 6 (03) 203-209
• 15 Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282 (18) 1737-1744
• 16 Fraguas Jr R, Henriques Jr SG, De Lucia MS. , et al. The detection of depression in medical setting: a study with PRIME-MD. J Affect Disord 2006; 91 (01) 11-17
• 17 American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, DC: American Psychiatric Publishing; 2013
• 18 Câmara RA, Köhler CA, Frey BN, Hyphantis TN, Carvalho AF. Validation of the Brazilian Portuguese version of the Premenstrual Symptoms Screening Tool (PSST) and association of PSST scores with health-related quality of life. Rev Bras Psiquiatr 2017; 39 (02) 140-146
• 19 Altman DG. Practical statistics for medical research . London: Chapman & Hall/CRC; 1990
• 20 Byrt T, Bishop J, Carlin JB. Bias, prevalence and kappa. J Clin Epidemiol 1993; 46 (05) 423-429
• 21 Bentz D, Steiner M, Meinlschmidt G. [SIPS--screening instrument for premenstrual symptoms. The German version of Premenstrual Symptoms Screening Tool to assess clinically relevant disturbances]. Nervenarzt 2012; 83 (01) 33-39